Skip to content

Stress-Induced Inflammation and Reward Processing

Stress-Induced Inflammation and Reward Processing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03828604
Enrollment
57
Registered
2019-02-04
Start date
2017-05-12
Completion date
2018-05-09
Last updated
2019-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress, Psychological

Keywords

reward processing

Brief summary

Anhedonia, or loss of interest or pleasure, is a key feature of depression and transdiagnostic construct in psychopathology. Both theory and compelling evidence from preclinical models implicates stress-induced inflammation as a key psychobiological pathway to anhedonic behavior; however, this pathway has not been demonstrated in human models. Further, although anhedonia may reflect dysregulation in multiple dimensions of reward, the extent to which stress-induced inflammation alters these dimensions is unclear. The current placebo controlled study used a standardized laboratory stressor task to elicit an inflammatory response in a sample of a healthy young women and evaluate effects of stress-induced inflammation on multiple behavioral indices of reward processing.

Detailed description

In this study we propose to examine the association between psychosocial stress, the stress-induced inflammatory response, and reward processing in a female undergraduate sample. Specifically, we will 1) examine effects of an acute psychosocial stressor on reward processing; 2) evaluate the association between stress-related changes in inflammation and reward processing; and 3) test key vulnerability factors that may moderate the association between stress and reward. To achieve these goals, this study will recruit 60 female undergraduate students to test effects of stress on reward processing in a 3.5 hour laboratory session. Participants will be randomly assigned to either experience a laboratory stressor or a placebo control, and will complete reward tasks 90 minutes post stress/placebo onset, at which point the peripheral inflammatory response to stress reaches its peak. The reward tasks are computerized behavioral tasks that assess three domains of reward processing: reward-learning, reward motivation, and reward sensitivity. Throughout the session, all participants will complete self-report measures of affect and provide blood and saliva samples for evaluation of the psychological and physiological stress response. Within one week prior to the session, participants will attend a 1 hour visit in which they complete baseline reward tasks and self-report questionnaires assessing mood, personality, early life stress, and health behaviors. In total, participants will complete two visits, with a duration of 4.5 hours. This study builds upon prior studies demonstrating immediate effects of acute stress on reward processing, and further tests for delayed effects of acute stress on reward processing. Furthermore, this will be the first study to examine inflammation as a mechanism linking stress to deficits in reward processing. Findings may inform theory of depression etiology and contribute to more specialized treatment that is targeted at specific symptoms of depression.

Interventions

BEHAVIORALStress; Trier Social Stress Task

Standardized acute psychosocial stressor

BEHAVIORALPlacebo Trier Social Stress Task

Active control version of the TSST

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Intervention model description

Acute Psychosocial stress vs. Non-stress active control

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 28 Years
Healthy volunteers
Yes

Inclusion criteria

* English fluency * Age 18-28 * Biologically female

Exclusion criteria

* Current illness * Presence or history of major medical conditions * Current or past diagnosis of alcohol use disorder * Use of tobacco * Use of immune-altering medications * Current pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Attentional Bias TaskPre-TSST/P-TSST and 110 min post-TSST/P-TSSTChange in attentional bias from pre to post-TSST/P-TSST
Probabilistic Reward Task - Reward ResponsivenessPre-TSST/P-TSST and 90 min post-TSST/P-TSSTChange in the magnitude of response bias from pre to post Trier Social Stress Task (TSST) or Placebo-TSST (P-TSST).
Effort Expenditure for Rewards Task - Reward MotivationPre-TSST/P-TSST and 120 min post-TSST/P-TSSTChange in amount of hard trials chosen from pre to post-TSST/P-TSST (overall, and at 3 levels of probability of potential rewards; low, medium, and high)

Secondary

MeasureTime frameDescription
Effort Expenditure for Rewards Task - Reward Sensitivity120 min post-TSSTStrength of the relationship between changes in reward magnitude and high effort trial choice as a function of degree of change in IL-6 following acute stress
Face Morphing TaskPre-TSST/P-TSST and 115 min post-TSST/P-TSSTChange in latency to detect emotional expressions

Other

MeasureTime frameDescription
Depressive symptomsChange in depressive symptoms from study entry to 4-month follow-upThe 20-item Center for Epidemiological Studies Depression Scale (CESD) is a self-report measure; participants are asked to rate how often they have experienced depressed feelings, attitudes, and behavioral symptoms during the past week (0 = rarely; 3 = most of the time). The total score range is 0 to 60, with higher scores indicating higher depressive symptoms.
Affective experience during the experimental sessionEntry, pre-TSST/P-TSST; during TSST/P-TSST; 60, 90, 120, 150 min post TSST/P-TSSTEmotional reactivity and recovery from the TSST/P-TSST will be assessed using items from the Positive and Negative Affect Schedule and the Profile of Mood States. Participants rate how they feel right now (that is, at the present moment) on a 1 (very slightly or not at all) to 5 (extremely) Likert scale. Average scores for subscales are reported, including positive and negative affect (7 items each), fatigue (8 items) vigor (5 items) and confusion (7 items). Participants also use visual analogue scales (VAS) to indicate how stressed, anxious, angry, confident, calm, socially connected and happy they are currently feeling on a 0 (not at all) to 100 (extremely) scale. The VAS are completed alongside the PANAS and three additional times during the TSST/P-TSST.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026